Ideaya Biosciences, Inc. · NASDAQ:IDYA
Ideaya Biosciences — Investor Presentation (September 2025)
28 slides from Ideaya Biosciences's investor presentation, Sep 23, 2025
Slide 1: IDEAYA Biosciences
September 2025 NASDAQ: IDYA IDEAYA Biosciences Improving Lives Through Transformative Precision Medicines NASDAQ: IDYA
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future financial performance of IDEAYA Biosciences, Inc. (the “Company”) and involve known and unknown risks, uncertainti
Slide 3: IDEAYA Vision to Build Industry Leading Precision Medicine Oncology Company
IDEAYA Vision to Build Industry Leading Precision Medicine Oncology Company Improving Lives through Transformative Precision Medicines Our mission is to advance the discovery, development, and commercialization of transformative precision medicines to address unmet medical needs in cancer Potential
Slide 4: IDEAYA Precision Medicine Oncology Platform to Deliver First-in-Class Therapies
IDEAYA Precision Medicine Oncology Platform to Deliver First-in-Class Therapies Fully-Integrated Target, Biomarker, Drug Discovery and Translational Capabilities Translational Research and Opportunity Expansion Drug Discovery and Genomics – DNA and RNA Analysis Pharmacological Validation Proteomics
Slide 5: IDEAYA Biosciences Highlights
IDEAYA Biosciences Highlights Leading Precision Medicine Oncology Biotechnology Company Advancing Potential First-in-Class Therapies Target Milestone Guidance on Broad Pipeline of 6 Clinical & 3 Preclinical (IND-enabling) Programs: PHASE 2/3 PHASE 1/2 PRECLINICAL DAROVASERTIB (PKC) IDE397 (MAT2A) ID
Slide 6: IDEAYA's Potential First-in-Class Precision Medicine Oncology Pipeline
IDEAYA’s Potential First-in-Class Precision Medicine Oncology Pipeline Potential Commercial Modality/Indication Biomarker Pre-clinical IND Enabling Phase 1 Phase 2 Program Goals / Achievements Collaborations Registrational (IDEAYA) +cMET1 Combination Ph 2 (AA) / Ph 3 registrational trial1 – targetin
Slide 7: Darovasertib Global Partnership Outside of the US
Darovasertib Global Partnership Outside of the US Partnership accelerates global development of Darovasertib Financial Terms: $530m + Royalties + Cost Share • Tier 1 International Oncology player with strong experience in niche oncology indications and international partnerships • Strong representat
Slide 8: Darovasertib: Potential to Broadly Impact Uveal Melanoma (UM)
Darovasertib Darovasertib: Potential to Broadly Impact Uveal Melanoma (UM) * Potential First-in-Class and Best-in-Class in (Neo)adjuvant UM and Metastatic UM (MUM) Mutations in GNAQ / GNA11 activate PKC Signaling, a genetic driver of Uveal Melanoma Darovasertib is an oral, potent and selective PKC i
Slide 9: Darovasertib and Uveal Melanoma Patient Journey
Darovasertib and Uveal Melanoma Patient Journey High Unmet Need and Multiple First-Line Opportunities in UM and MUM1 +95% of UM patients harbor GNAQ/GNA11 mutation Uveal Melanoma Patient Journey Neoadjuvant UM Adjuvant UM MUM No Approved Therapies No Approved Therapies HLA-A2-Negative2 Daro + Crizo
Slide 10: Daro + Crizo Phase 2 Efficacy: First-Line MUM and Any-Line MUM Best Tumor Response
Daro + Crizo Phase 2 Efficacy: First-Line MUM and Any-Line MUM Oral Presentation Compelling Overall Response Rate (ORR) by RECIST 1.1 Observed 60% Darovasertib + Crizotinib Phase 2 Confirmed 45% ORR and 90% DCR 50% Response by RECIST 1.1 Evaluable First-Line MUM (n=20) Best Tumor Response (%) 40% Fi
Slide 11: Median PFS in First-Line, Any-Line and Hepatic-Only MUM
Median PFS in First-Line, Any-Line and Hepatic-Only MUM Oral Presentation Observed Compelling Median Progression Free Survival with Encouraging Trend MUM Swimlane Plot Darovasertib + Crizotinib Phase 2 Median Progression Free Survival • First-Line (n=20): 7.1 months • Any-Line (n=63): 6.8 months • H
Slide 12: Review of Published Clinical Data in MUM
Review of Published Clinical Data in MUM Cabozantinib Mono / Darovasertib + Crizotinib Selumetinib + DTIC Ipi + Nivo Tebentafusp Crizotinib Mono Target / Mechanism PKC + cMET cMET MEK + Chemotherapy CTLA4 + PD-1 HLA-A2-0201 Bi-Specific Study Name(s) NCT03947385 A0912011 / NCT050630582 NCT019747523 N
Slide 13: Darovasertib Neoadjuvant Therapy: Ph2 Company Sponsored & Ph2 IST UM Trials
Darovasertib Neoadjuvant Therapy: Ph2 Company Sponsored & Ph2 IST UM Trials 61% (19 of 31) Observed Eye Preservation and 49% (24 of 49) with >30% Tumor Reduction* 60.0 ~59% (29 of 49) observed >20% Tumor Reduction Clinical Efficacy (n=49) ~49% (24 of 49) observed ≥ 30% Tumor Reduction Evaluable Pati
Slide 14: Darovasertib Ph2/3 Registrational Trial Designs in MUM & Neoadjuvant UM
Darovasertib Ph2/3 Registrational Trial Designs in MUM & Neoadjuvant UM Broad opportunity to address unmet need in MUM and Save the Eye and Protect Vision in Neoadjuvant UM Metastatic Uveal Melanoma Ph2/3 Registrational Trial1 Median Median PFS OS Phase 2 Phase 3 Δ Daro + Crizo Primary Endpoints (BI
Slide 15: MAT2A Inhibition is Synthetic Lethal with MTAP-Deletion
MAT2A Inhibition is Synthetic Lethal with MTAP-Deletion MAT2A Strategies to address MTAP-/- Prevalence in ~15% of all Solid Tumors MTAP-MAT2A Synthetic Lethality Biology Robust monotherapy activity in lung, urothelial and gastric PDX MTAP-/- Gastric MTAP-/- Urothelial Mean Tumor Volume (mm3) ± S.E.M
Slide 16: IDE397: Phase 2 Potential First-in-Class MAT2A Inhibitor
IDE397: Phase 2 Potential First-in-Class MAT2A Inhibitor ~48k U.S. Annual Incidence in MTAP-Deletion NSCLC and Urothelial Cancer High Unmet Need: No FDA-Approved Therapies for MTAP-Deletion Solid Tumors U.S. Annual Incidence in Priority Tumor Types U.S. Annual Incidence in Potential Expansion Tumor
Slide 17: IDE397 Phase 2 Clinical Efficacy in MTAP-Deletion NSCLC & UC
IDE397 Phase 1 Clinical Efficacy in MTAP-Deletion NSCLC & UC Best Response by RECIST 1.1 at 30mg QD Phase 2 expansion dose1 Efficacy by RECIST 1.11 ~ 33% ORR by RECIST 1.1 = 9 PR or CR out of 27 Evaluable Pts 27 9 of 9 responses have been confirmed Best Response, n (%) Best Response by RECIST (% cha
Slide 18: IDE397 + Trodelvy Urothelial Cancer MTAP-Deletion Patients
IDE397 + Trodelvy® Urothelial Cancer MTAP-Deletion Patients (n=16) 33% ORR at Dose Level 1 (DL1) and 57% ORR at Dose Level 2 (DL2) by RECIST 1.1 Best Response by RECIST 1.1 ORR by RECIST 1.1, n (%) 40.00% Best Response by RECIST (% change from baseline) * DL1 = IDE397 15 mg QD + Trodelvy® 10 mg/kg D
Slide 19: IDE397 Phase 1/2 Clinical Development Plan in MTAP-Deletion Solid Tumors
IDE397 Phase 1/2 Clinical Development Plan in MTAP-Deletion Solid Tumors Clinical Strategic Focus on High Conviction Rational Combinations IDE397 is strategically well positioned to evaluate both monotherapy and clinical IDE397 – Clinical Profile combinations in MTAP-deletion solid tumors Exposure-d
Slide 20: IDE849 (SHR-4849): Phase 1 DLL3 TOP1i ADC
DLL3 IDE849 (SHR-4849): Phase 1 DLL3 TOP1i ADC First-in-Class Potential and Targeting Lineage Survival Oncogene Activity IDE849 (SHR-4849) potential Robust activity in DLL3+ CDX/PDX with exceptional first-in-class/best-in-class linker/payload stability in circulation Deep regressions observed in DLL
Slide 21: DLL3 Expression is Upregulated in a Broad Range of Solid Tumor Types
DLL3 Expression is Upregulated in a Broad Range of Solid Tumor Types >100k Potential Addressable Population in the US Alone Table of DLL3 Upregulated Expression Solid Tumors Addressable US Population: SCLC and NETs only 32% 5% 4% Tumor US Incidence DLL3 Addressable US Type (2024), 000 Expressed, % P
Slide 22: IDE849 (SHR-4849): Phase 1 Tumor Response in SCLC
IDE849 (SHR-4849): Phase 1 Tumor Response in SCLC 2.4 mg/kg 3.0 mg/kg 3.5 mg/kg 4.2 mg/kg Total (≥2.4 mg/kg) 2L Setting All 2L Setting All 2L Setting All 2L Setting All 2L Setting All (n=10) (n=19) (n=8) (n=18) (n=16) (n=31) (n=1) (n=3) (n=35) (n=71) ORR, n (%; 8 (80.0%; 14 (73.7%; 6 (75.0%; 12 (66.
Slide 23: IDE849 (SHR-4849): Phase 1 PFS in SCLC
IDE849 (SHR-4849): Phase 1 PFS in SCLC Total (≥2.4 mg/kg) 2L Setting All (n=42) (n=86) Events, n (%) 8 (19.0%) 22 (25.6%) Median (95% CI), months NR (4.4-NR) 6.7 (4.4-NR) 93.3% 83.3% 3-month rate, % (95% CI) (75.2-98.3) (71.0-90.7) 59.0% 55.3% 6-month rate, % (95% CI) (31.2-78.8) (37.8-69.7) 23 PFS,
Slide 24: IDE849 (SHR-4849): Potential First-in-Class DLL3 TOP1i ADC
IDE849 (SHR-4849): Potential First-in-Class DLL3 TOP1i ADC IDEAYA Clinical Development Plan IDE849 Monotherapy Dose Escalation and Expansion Dose Escalation Expansion Cohort: SCLC Expansion Cohort: NETs IDE849 Combination with IDE161/PARG IDE849 + IDE161: SCLC and NETs • Potential monotherapy path i
Slide 25: IDE275 (GSK959): Phase 1 Werner Helicase Non-Covalent Inhibitor
IDE275 (GSK959): Phase 1 Werner Helicase Non-Covalent Inhibitor Phase 1 Clinical Development Plan in MSI-High Solid Tumors IDE275 (GSK959) Werner Helicase Werner Clinical Development Plan Inhibitor PART 1: Monotherapy PART 3: Combination • IDE275 (GSK959) has demonstrated Dose Escalation Dose Escala
Slide 26: IDE705 (GSK101): Potential First-in-Class Ph1 Pol Theta Helicase Inhibitor
Pol Theta IDE705 (GSK101): Potential First-in-Class Ph1 Pol Theta Helicase Inhibitor Phase 1 in Combination with Niraparib (PARPi) Pol Theta Helicase In Vivo Activity BRCA 1/2 Clinical Reversions Clinical Development Strategy IDE705(GSK101) + PARPi Pol Theta Helicase PARP BRCA Reversions Mediated by
Slide 27: Development Candidates: IDE892 IND Filed and Targeting 2 INDs in Q4 2025
Development Candidates: IDE892 IND Filed and Targeting 2 INDs in Q4 2025 IDE892: PRMT5iMTA IDE034: B7H3/PTK7 Bispecific ADC IDE574: Dual KAT6/KAT7 Inhibitor MTA-templated target Robust pathway Dual potency design Strong and selective cellular αB7-H3 αPTK7 challenge target binding by IDE574 binding m
Slide 28: Building a Fully-Integrated Biotech in Precision Medicine Oncology
Building a Fully-Integrated Biotech in Precision Medicine Oncology Foundational Potential First-in-Class Clinical Pipeline and Drug Discovery Platform CLINICAL PROGRAMS DEVELOPMENT CANDIDATES PRECLINICAL PROGRAMS Ph 2/3 – Darovasertib (PKC) 1,2 Ph 2 – IDE397 (MAT2A) 1 IDE034 (B7H3/PTK7 Bi-Specific A
IDEAYA Biosciences — Investor Presentation (September 2025) on 6ix